<DOC>
	<DOCNO>NCT03056755</DOCNO>
	<brief_summary>Efficacy safety treatment alpelisib plus endocrine therapy patient HR+ , HER2-negative aBC , PIK3CA mutation , whose disease progress CDK 4/6 treatment aromatase inhibitor ( AI ) fulvestrant</brief_summary>
	<brief_title>Efficacy Safety Treatment With Alpelisib Plus Endocrine Therapy Patients With HR+ , HER2-negative aBC , With PIK3CA Mutations , Whose Disease Has Progressed After CDK 4/6 Treatment With Aromatase Inhibitor ( AI ) Fulvestrant</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Aromatase Inhibitors</mesh_term>
	<mesh_term>Letrozole</mesh_term>
	<mesh_term>Fulvestrant</mesh_term>
	<mesh_term>Estradiol</mesh_term>
	<criteria>patient male female 18 year old Patient identify PIK3CA mutant status Patient confirm HER2negative advance breast cancer ( aBC ) Patient must diagnose aBC document progression CDK 4/6 treatment ( adjuvant metastatic setting ) Patient histological and/or cytological confirm ER+ and/or PgR+ aBC Patient either measurable disease per RECIST v1.1 least one predominantly lytic bone lesion must present ECOG function great equal 2 Patient adequate bone marrow function Patient adequate liver renal function patient receive prior treatment PI3K inhibitor patient clinically manifest diabetes mellitus , document steroid induce diabetes mellitus Patient concurrent malignancy malignancy within 3 year study screen period , exception adequately treat , basal squamous cell carcinoma , nonmelanoma skin cancer curatively resect cervical cancer Patient receive radiotherapy ≤ 4 week limited field radiation palliation ≤ 2 week prior enrollment , recover grade 1 well related side effect therapy History acute pancreatitis within 1 year screen past medical history pancreatitis Bilateral diffuse lymphangitis carcinomatosis Patients central nervous system ( CNS ) involvement unless meet ALL follow criterion : At least 4 week prior therapy completion ( include radiation and/or surgery ) start study treatment Clinically stable CNS tumor time screen untreated without evidence progression least 4 week treatment determine clinical examination brain imaging ( MRI CT ) screen period stable low dose steroid 2 week prior initiate study treatment Patient severe liver impairment ( Child Pugh score B/C Patient impairment gastrointestinal ( GI ) function GI disease may significantly alter absorption study drug Patient document pneumonitis active requiring treatment</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>advanced breast cancer</keyword>
	<keyword>PIK3CA</keyword>
	<keyword>CDK 4/6 inhibitor</keyword>
	<keyword>fulvestrant</keyword>
	<keyword>letrozole</keyword>
	<keyword>HR+</keyword>
	<keyword>HER-negative</keyword>
	<keyword>post menopausal</keyword>
</DOC>